DCBLD2 Target Biology and Scientific Background

DCBLD2 (Discoidin, CUB and LCCL Domain Containing Protein 2), also referred to as CLCP1 (CUB, LCCL-homology, coagulation factor V/VIII homology domains protein 1), is a type I transmembrane protein that plays important roles in cell signaling, vascular biology, and tumor progression. The protein contains multiple conserved extracellular domains — including discoidin, CUB, and LCCL modules — which mediate protein–protein interactions relevant to angiogenesis, cell adhesion, and migration.

Research has implicated DCBLD2 in the regulation of receptor tyrosine kinase (RTK) signaling, particularly as a co-receptor that modulates growth factor pathways. Expression of DCBLD2 has been reported in endothelial cells and various tumor types, making it a protein of interest in oncology and vascular research. Accurate detection of DCBLD2 requires validated, highly specific antibody reagents.

Antibody Specifications and Formulation

The DCBLD2 Mouse mAb (SKU: Ab351202) is a monoclonal antibody produced in mouse against the DCBLD2 target antigen. The product is supplied in PBS (phosphate-buffered saline) only, without additional carrier proteins or preservatives unless otherwise stated on the Certificate of Analysis (CoA). Researchers should consult the CoA for lot-specific details including concentration, purity, and confirmed reactivity.

Key specification highlights:

• Antibody format: Mouse monoclonal antibody (IgG isotype to be confirmed per CoA)
• Buffer: PBS
• Source reference: absea#KC-2663
• SKU: Ab351202

Because the antibody is formulated in PBS without stabilizers such as BSA or glycerol, it is especially important to aliquot the stock upon receipt to minimize the risk of activity loss from repeated freeze-thaw cycles.

Recommended Applications and Usage Guidelines

Monoclonal antibodies against DCBLD2 are generally suitable for a range of immunological techniques. Researchers should verify application suitability in their specific experimental system by consulting the product datasheet and CoA. Typical applications for anti-DCBLD2 monoclonal antibodies include:

• Western Blot (WB): Detection of denatured DCBLD2 under reducing or non-reducing conditions. Optimize primary antibody dilution empirically.
• Immunofluorescence (IF) / Immunocytochemistry (ICC): Visualization of DCBLD2 localization in fixed cell preparations.
• Immunohistochemistry (IHC): Detection of DCBLD2 expression in formalin-fixed, paraffin-embedded (FFPE) tissue sections, relevant for tumor or vascular tissue studies.
• Enzyme-Linked Immunosorbent Assay (ELISA): Quantification of DCBLD2 in solution-phase formats.
• Flow Cytometry: Detection of DCBLD2 expression on the surface of intact cells when the antibody recognizes extracellular epitopes.

Note: Specific validated applications for Ab351202 should be confirmed on the product datasheet. Not all applications listed above may have been formally validated for this lot.

Storage, Handling, and Quality Considerations

Proper storage and handling of the DCBLD2 Mouse mAb are critical to maintaining antibody performance over time. Because the product is formulated in PBS without cryoprotectants (e.g., glycerol) or carrier proteins (e.g., BSA), the following best practices are strongly recommended:

• Short-term storage (≤1 month): Store at 2–8°C (4°C refrigerator).
• Long-term storage: Aliquot into single-use volumes and store at −20°C or −80°C. This minimizes freeze-thaw cycles which can cause antibody aggregation and loss of binding activity.
• Avoid repeated freeze-thaw: Each freeze-thaw cycle can degrade antibody integrity. Prepare small working aliquots upon receipt.
• Sterile handling: Use sterile, low-protein-binding tubes and pipette tips to prevent contamination and non-specific adsorption.
• Centrifugation before use: If any precipitate is observed, briefly spin the tube (e.g., 10,000 × g for 1 min) and use the supernatant.

Always refer to the lot-specific Certificate of Analysis (CoA) provided with the product for confirmed concentration, storage instructions, and expiry information.

Experimental Tips for Reliable DCBLD2 Detection

Achieving consistent and reproducible results with the DCBLD2 Mouse mAb requires careful experimental design. The following tips are based on general best practices for monoclonal antibody use in research applications:

1. Titrate the antibody: Always perform a dilution series to identify the optimal concentration that maximizes specific signal while minimizing background. Starting dilutions of 1:500–1:2000 for WB and 1:50–1:200 for IHC/IF are common starting points, but must be optimized per system.
2. Use appropriate positive and negative controls: Include a lysate or tissue known to express DCBLD2 (positive control) and a DCBLD2-negative sample or isotype control antibody (negative control) in every experiment.
3. Blocking optimization: For WB applications, blocking with 5% non-fat milk or BSA in TBST is standard. For IHC, use species-matched blocking serum to reduce background from secondary antibodies.
4. Antigen retrieval (IHC): For FFPE sections, heat-induced epitope retrieval (HIER) in citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) may be required. Optimize retrieval conditions empirically.
5. Secondary antibody compatibility: Select an anti-mouse secondary antibody appropriate for the detection system (e.g., HRP-conjugated for colorimetric WB/IHC, or fluorophore-conjugated for IF/flow cytometry).